We have designed a transgene that encodes a scFv(G250) chimeric receptor, which is specific for carboxyanhydrase IX (G250-ligand, G250L), a molecule overexpressed by renal cell cancer (RCC). Retroviral transduction of this transgene into primary human T lymphocytes confers these cells with specific functional responses towards G250L-positive RCC cells. In preparation of a clinical phase (I/II) study in RCC patients, we set up a protocol for gene transduction and expansion of primary human T cells. For this purpose, we directly compared two packaging cell lines, that is, the GALV-pseudotyped MLV producing cell line PG13, and the MLV-A-producing cell line Phi-NX-Ampho (a.k.a. Phoenix-A). We generated and characterized stable scFv(G250)-positive clones of both PG13 and Phoenix cells and optimized the retrovirus production conditions. Transductions of primary human T cells yielded 30-60% scFv(G250) þ T cells using PG13-derived retrovirus versus up to 90% scFv(G250) þ T cells using Phoenix-derived retrovirus. The median number of transgene integrations per scFv(G250) þ T cell differed only 1.5-fold as determined by real-time PCR (mean number of integrations per T cell 2.6 and 3.7 for PG13 and Phoenix-based transductions, respectively). In addition, T cells transduced with Phoenix-derived retrovirus showed, on a per cell basis, 10-30% higher levels of scFv(G250)-mediated TNFa production and cytolysis of G250L þ RCC cells than T cells transduced with PG13-derived retrovirus. The improved functional transduction efficiency together with a limited increase in the number of integrations per recipient cell, made us select Phoenix clone 58 for our clinical immunogene therapy study.
Introduction
The transfer of genes encoding antigen-specific receptors into T cells (i.e., genetic retargeting) represents an attractive strategy to induce antigen-specific immunity. We have developed a single chain antibody-type receptor, scFv(G250)-CD4g (scFv(G250)), which is specific for carboxyanhydrase IX (G250-ligand, G250L), a molecule overexpressed by renal cell cancer (RCC). Upon retroviral transduction, primary human T cells express the scFv(G250) and exerted scFv(G250)-mediated effector functions, such as G250L-induced cytokine production and killing of G250L þ RCC. [1] [2] [3] In preparation of a phase I/II immunogene therapy trial of metastatic RCC, we have developed a protocol for gene transduction and expansion of primary human T lymphocytes that meets good clinical practice (GCP) criteria. 1 This clinical protocol was based on the use of retroviral particles produced by a stably transduced clone of the packaging cell line PG13 (i.e., clone 1.2) and routinely yielded 30-60% transduction efficiencies in T lymphocytes from both healthy individuals and RCC patients. 1 Nevertheless, we did not proceed to the clinical use of PG13-derived retroviral particles for the following reasons. First, there is only limited clinical experience with murine Moloney leukemia virus (MLV)-based vectors that are pseudotyped for the gibbon ape leukemia virus (GALV) envelope. Second, safety testing for GALVderived replication-competent retrovirus (RCR) is currently only at a validation stage, as there is currently no appropriate positive GALV RCR reference standard available. In contrast, the ATCC-VR1450 is an appropriate reference standard for MLV RCR testing (FDA/ CEBR Guidance for Industry: 'Supplemental Guidance 4 To address these issues and in an attempt to further improve transduction efficiencies, we compared the high-titer amphotropic MLV-producing human cell line Phi-NX-Ampho (a.k.a. Phoenix-A) 5 with the murine PG13 cell line 1 for their use as retroviral-packaging cells to transduce primary human T cells with our scFv(G250).
Here we demonstrate that Phoenix-A-derived scFv(G250) retroviral particles outperform those derived from PG13 with respect to functional transduction efficiencies of primary human T cells, that is, resulting in a higher proportion of scFv(G250) þ T cells, which on a per positive cell basis exerted higher levels of receptormediated immune functions.
Materials and methods
Cells and antibodies PG13 clone 1.2, 1 and Phoenix-A 5 were cultured in DMEM medium containing 10% clinical-grade fetal calf serum (FCS, Summit Biotechnology, FtCollins, CO), 2 mM L-glutamin, 1% MEM-NEAA and 1% penicillin/ streptomycin. Media and supplements were purchased from Bio-Whittaker (Verviers, Belgium). Target cell lines used for cytotoxicity and cytokine production tests were the G250L þ RCC cell line SKRC-17 MW1-clone 4, the G250L À RCC cell line SKRC-17 PBJ-clone 1, and the Daudi Burkitt's lymphoma cell line. G250 mAb was from Dr S Warnaar (Wilex AG, Munich, Germany), and the G250 anti-idiotype mAb NUH-82 (IgG 1 ) from Dr E Oosterwijk (Nijmegen, The Netherlands). Goat anti-mouse IgG 1 (GAM) conjugated to phyco-erythrin was purchased from Southern Biotechnology (Birmingham, AL).
Generation and characterization of the scFv(G250)
þ Phoenix clone 58 Phi-NX-Ampho (Phoenix-A; see: http://www.stanford.edu/ group/nolan/retroviral_systems/phx.html) was used to generate a clone stably producing scFv(G250) geneexpressing retroviruses (MLV-A typed SFG particles). In short, Phoenix cells were transduced with GaLVpseudotyped SFG retroviruses via cocultivation with irradiated 293T cells that were transfected with the plasmids MLV gag/pol (pHIT60), GaLV env (pCOLT-GALV) and pSTITCH scFv(G250). 2 Limiting dilution cultures generated 54 Phoenix clones expressing high levels of the scFv(G250) receptor as measured by flow cytometry using the NUH82 mAb. Only five of these clones produced high virus titers as assessed by titration on a permissive cell line (i.e., 293). Subsequently, we selected Phoenix clone 58 because its retrovirus-containing culture supernatant (RTVsup) showed the best functional transduction of primary human T cells. PG13 clone 1.2 1 was generated and selected according to the same procedure, with similar cloning efficiency as described here for Phoenix clone 58, but using Mus dunni cells for virus titer assessment.
Optimization of virus production
Clinical grade PG13 clone 1.2 retrovirus-containing culture supernatant (RTVsup) was defined as: RPMI1640 supplemented either 2% human serum albumin (HSA, CLB, Amsterdam, The Netherlands), or 10% 'clinical grade' FCS and produced at 321C. 1 To optimize virus production conditions for the Phoenix clone 58 cell line, we tested the following culture media: (a) DMEM; (b) RPMI 1640; (c) synthetic serum-free media AIM V (Invitrogen, Grand Island, NY) and (d) X-VIVO 15. Medium supplements used were either 2% HSA or 10% 'clinical-grade' FCS. In addition, we tested production volume, temperature and time, cell confluency, single versus sequential harvesting and type of production container. Following harvest, RTVsup was filterered (0.45 mm), aliquoted, and kept frozen at À801C until use.
Transduction and analysis of primary human T cells
PBMCs from healthy donors were activated, transduced and cultured as described. 1 Flow cytometry. scFv(G250) surface expression by PG13 clone 1.2, Phoenix clone 58, and transduced T cells was determined by indirect immuno-fluorescence as described. 1 Cytotoxicity assay. Cytotoxic activity of transduced T cells was measured in a standard 4 h 51 Cr-release assay. 1 The percentage of specific cytolysis was expressed as weighted mean of specific lysis (WMSL), according to the following formula:
where n is the number of E:T ratio's, SLi is the percentage of specific lysis at E:T ratio Et i , and Et i is effector-to-target (E:T) ratio i. The WMSL ET 10 expresses the average cytotoxic activity standardized at an E:T ratio of 10, being the mean log of the E:T ratio range used. In experiments aimed at specific blocking of G250L-specific lytic activity, G250 mAb (25 mg/ml final concentration) was added to the target cells 15 min before addition of the effector T cells.
Production of cytokines. To quantify secreted cytokines, 6 Â 10 4 transduced T cells were cultured for 24 h in the presence of either 2 Â 10 4 adherent G250L þ or G250L
À RCC stimulator cells and rIL-2 (360 IU/ml), in 96-well microtiter plates as described. 1 The levels of IFNg, TNFa, IL-4, IL-5, and IL-10 in the cell-free culture supernatants were measured by cytokine bead array (CBA, BD Biosciences), according to the suppliers' conditions. Cytokine production was expressed as pg cytokine produced by 10 4 scFv(G250) þ T cells per 24 h.
Quantitative real-time PCR. Genomic DNA was isolated from aliquots of transduced T cells using the QIAamp s DNA mini kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed as described (Lamers et al., 2005, submitted) . Serial 10-fold dilutions of pSTITCH-scFv(G250) plasmid DNA (ranging from 100 pg-0.1 fg) were included to generate a standard curve in each PCR assay. The assay sensitivity was 14 transgene copies per 100 ng total DNA. One copy of pSTITCHscFv(G250) plasmid DNA equals 0.7 Â 10 À2 fg and the absolute number of copies of scFv(G250) DNA in experimental samples was calculated as follows: copy number ¼ fg scFv(G250)-specific DNA/0.7 Â 10 À2 fg.
Results
Characterization of Phoenix clone 58 and optimization of RTVsup production Southern blot analysis (Dr E Bakker, Leiden, The Netherlands), and DNA sequence analysis (BaseClear, Leiden) demonstrated that scFv(G250) þ Phoenix clone 58 cells contained two intact copies of the provirus SFG-scFv(G250). In addition we demonstrated stable membrane expression of the scFv(G250) receptor over a period of at least 100 passages (about 12 months). Optimal conditions to produce Phoenix clone 58 RTVsup were found to be similar to those defined previously for PG13 clone 1.2, 1 except for the medium composition. Phoenix clone 58-derived RTVsup providing the highest efficiency to functionally transduce T cells was obtained using DMEM or RPMI-1640 supplemented with 10% 'clinical grade' FCS, and following production at 321C. Since we culture T cells in RPMI-1640-based medium prior to and following clinical transduction, we chose RPMI-1640 þ 10% FCS medium to generate Phoenix clone 58-derived RTVsup.
Retrovirus-containing supernatant produced by Phoenix clone 58 outperforms that produced by PG13 clone 1.2 for functional T-cell retargeting The RTVsup from Phoenix clone 58 and PG13 clone 1.2, produced according to individually optimized conditions (see above) were compared for their ability to transduce primary human T cells. In 10 separate experiments primary human T cells derived from two or three donors were transduced with either Phoenix clone 58 or PG13 clone 1.2-derived RTVsup and compared with respect to the expression of scFv(G250) and levels of antigenspecific cytotoxicity and cytokine production. (Figure 1b) . In addition, kinetics of the scFv(G250) membrane expression by human T cells was faster following transduction with Phoenix clone 58-derived RTVsup (median day (after T-cell activation) of maximum % scFv(G250) (Figure 1d ). (c) scFv(G250) receptor-mediated cytolysis: T cells transduced with Phoenix clone 58-derived RTVsup exerted increased cytolytic activity towards G250L þ RCC cells (median % WMSL ET 10 at day 13-16: 58%, range 32-87%, n ¼ 22) when compared with T cells transduced with PG13 clone 1.2-derived RTVsup (38%, range 7-57%, n ¼ 22; paired t-test Po10 À8 ) (Figure 2a) . In order to make a fair comparison between both transduction systems, we decided to assess the scFv(G250)-mediated cytotoxic capacity on a per scFv(G250) þ T cell basis. To this end the proportions of scFv(G250) þ cells in suspensions from both sets of transduced T cells were adjusted to about 40% by the addition of nontransduced T cells from parallel control cultures. The resultant T cell suspensions contained 43-46% scFv(G250) þ T cells (n ¼ 4) and 42-45% scFv(G250) þ T cells (n ¼ 4) for Phoenix RTVsup and PG13 RTVsup-transduced T cells, respectively. Subsequently, T cell cytotoxicity of G250L þ RCC cells was determined in 0.5, 1, 2, and 4 h assays. We observed a faster kinetics of the scFv(G250)-mediated cytotoxicity for T cells transduced with Phoenix clone 58 versus PG13 clone 1.2 RTVsup (summarized in Figure 2b ). Of note, the adjusted Phoenix RTVsup-transduced T cell mixtures had two-fold higher scFv(G250) membrane expression intensities than those transduced with PG13 RTVsup. On the contrary, we observed a slightly higher activated kill activity for T cells transduced with PG13 versus Phoenix RTVsup (Figure 2c ). (d) scFv(G250) receptor-mediated cytokine production:
Upon specific interaction with the G250L þ RCC cells, scFv(G250) þ T cells produced considerable amounts of IFNg, IL-5, and IL-4, and significant, but relative low levels of TNFa, and no IL-10, irrespective of the transduction system used (Figure 2e ). Low but significant levels of IFNg and IL-5 were also produced by the scFv(G250) þ (Figure 2d ). T cells transduced with PG13 RTVsup produced higher levels of IFNg and IL-5 following both nonspecific and G250L-specific stimulation when compared with Phoenix RTVsuptransduced T cells (Figure 2d, e) . The nonspecific production of cytokines, and in particular of IFNg, by PG13 RTVsup-transduced T cells coincides with a slightly increased level of activated kill activity of these cells (Figure 2c ). In contrast, upon specific stimulation, significantly higher levels of TNFa were produced by Phoenix versus PG13 RTVsuptransduced T cells (paired t-test P ¼ 0.03; Figure 2e ). This last observation was extended and confirmed in eight out of 10 tested donors (Figure 2f ).
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Discussion
Clinical application of genetically modified human T cells depends on: (i) an efficient clinical-scale transduction protocol, and (ii) a clinical-grade high-titer retroviral vector supernatant. Previously, we have developed a clinical protocol that meets GCP criteria regarding gene transduction and expansion of primary human T cells. 1 In this report, we (i) generated and characterized Phoenix clone 58, stably expressing the scFv(G250) receptor, (ii) defined optimal GMP conditions to produce MLV-A viruses, and (iii) compared RTVsups produced by Phoenix clone 58 and the earlier reported PG13 clone 1. human T cells with the scFv(G250) transgene. The RTVsup of Phoenix clone 58 resulted in significantly higher transduction efficiencies (ranges: 77-93 versus 27-58%) of the scFv(G250) receptor gene into primary human T cells when compared with RTVsup of PG13 clone 1.2. Importantly, on a per cell basis, Phoenix clone 58-RTVsup-transduced T cells showed significantly improved scFv(G250) receptor-mediated functions, that is, TNFa production and cytolysis of G250L þ RCC cells. The higher transduction efficiencies of primary human T cells we found with RTVsup produced by Phoenix versus PG13 packaging cells may be the consequence of one of the following reasons. First, Phoenix RTVsup may be of a higher titer of infectious particles when compared to PG13 RTVsup. This contention is supported by the fact that Phoenix clone 58 contains two integrated copies of the transgene svFvG250, and five copies of both helper elements (data not shown), whereas PG13 clone 1.2 contains only one copy of the transgene, and one copy of each helper element. 1 The different types of envelopes of the two engineered retroviruses (i.e., MLV-A and GALV for Phoenix and PG13-derived retroviruses, respectively) does not allow a direct comparison of infectious virus titers as they require different indicator cell lines for titration. Nevertheless, the higher number of scFv(G250) DNA integrations per transduced T cell (median: 3.7 versus 2.6 for Phoenix and PG13 transductions, respectively), together with the higher transgene expression levels and the improved scFv receptor-mediated functions on a per cell basis do suggest that the infectious virus titer of Phoenix RTVsup is higher than that of PG13 RTVsup. Our observations on transgene copy numbers in transduced primary human T cells are in line with those by Kustikova et al., 6 who compared retroviral transduction efficiencies in mass cultures of indicator cell lines and the actual number of integrated vector copies in single cells, and demonstrated that higher transduction efficiencies correlated with increased transgene integration numbers. Second, ECM compounds, such as chondroitin sulfate proteoglycan secreted by murine PG13 but not human Phoenix cells may scavenge viral particles and thus hamper gene transduction in human cells. 4 Third, human T cells may be more susceptible for infection with Amphotropic-enveloped than for with GALV-enveloped MLV retroviruses.
Phoenix clone 58-RTVsup-transduced T cells, having higher densities of the scFv(G250) receptor, showed improved scFv(G250) receptor-mediated cytolysis of G250L þ RCC cells when compared to PG13 RTVsuptransduced T cells. The existence of a functional balance between the level of receptor expression on T cells on the one hand and the target antigen density on tumor cells on the other hand, 3 predicts that these 'high scFv(G250) receptor expressing' T cells will enable kill renal cancer cells that express (very) low levels of the G250L target antigen. In addition, the antigen-specific production of TNFa by Phoenix T-cell transductants was increased when compared to that of PG13 T-cell transductants, being in agreement with observations that higher receptor expressions induce higher levels of specific TNFa production. 3, 7 The production of TNFa may be of special interest in the context of T-cell retargeting to tumors, since this cytokine is a major effector molecule for direct as well as indirect antitumor activities.
Recently, leukemia as a consequence of genome insertion of replication-defective retroviral vectors in hematopoietic stem cells has become clinical reality. 8 In this respect the reduction of the number of transgene integrations per cell is considered a prominent safety issue. Transduction strategies of primary hematopoietic stem cells should ideally result in a single integration per cell. Empirical studies have shown that transduction efficiencies in bulk cultures should on average not exceed 30% to obtain one integration per cell. 6 Although, the safe treatment of a genetic defect in progenitor cells may warrant the introduction of only a single copy of the corrective gene, this may not hold true for immunogene therapy using genetically retargeted differentiated T cells. In fact, to day no cases of insertional oncogenisis in T cells have been reported in clinical protocols and in preclinical models. 9 Moreover, it is suggested that efficient tumor eradication by (genetically retargeted) T cells requires high avidity T cells, 3, 10 which can be established by a high expression level of the introduced receptor, that is, multiple transgene copies per T cell. Considering the necessity to optimally retarget T cells together with the lack of data pointing to the risk of insertional mutagenesis in differentiated T cells, we decided to use Phoenix clone 58 for the production of clinical grade RTVsup in our clinical immunogene therapy protocol. Following cell banking and thorough testing, a master cell bank was established that performed well in a GMP production facility regarding cell growth and retrovirus production. The clinical lot of Phoenix clone 58-RTVsup, showing similarly high functional transduction efficiencies as in our preclinical studies reported here (i.e., median 85%, range 72-87% of primary human T cells obtained from five healthy donors), has been successfully applied in our phase (I/ II) clinical study. 
